Subsequent second- and third-generation ALK-TKIs have been developed to overcome the limitations of first-generation agents, including poor blood-brain barrier penetration and acquired drug resistance, and to target ALK-resistant mutations that emerge in some NSCLC patients during treatment. Here, ALK is linked to non-small cell lung carcinoma.